{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:53Z","timestamp":1793502713398,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T00:00:00Z","timestamp":1567555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-4409-1","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T10:03:34Z","timestamp":1567591414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-1829","authenticated-orcid":false,"given":"Basem M.","family":"Alraddadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Saeedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Qutub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Alshukairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Hassanien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"key":"4409_CR1","unstructured":"Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. \n                    https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/259462\/9789241550178-eng.pdf?sequence=1\n                    \n                  ."},{"issue":"3","key":"4409_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/j.semdp.2019.04.011","volume":"36","author":"JD Lutgring","year":"2019","unstructured":"Lutgring JD. Carbapenem-resistant Enterobacteriaceae: an emerging bacterial threat. Semin Diagn Pathol. 2019;36(3):182\u20136.","journal-title":"Semin Diagn Pathol"},{"issue":"3","key":"4409_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14787210.2017.1268918","volume":"15","author":"K Escandon-Vargas","year":"2017","unstructured":"Escandon-Vargas K, Reyes S, Gutierrez S, Villegas MV. The epidemiology of carbapenemases in Latin America and the Caribbean. Expert Rev Anti-Infect Ther. 2017;15(3):277\u201397.","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"1","key":"4409_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1469-0691.2011.03478.x","volume":"18","author":"D Ben-David","year":"2012","unstructured":"Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012;18(1):54\u201360.","journal-title":"Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"issue":"12","key":"4409_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1086\/592412","volume":"29","author":"G Patel","year":"2008","unstructured":"Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099\u2013106.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"4409_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154092","volume":"11","author":"MV Villegas","year":"2016","unstructured":"Villegas MV, Pallares CJ, Escandon-Vargas K, Hernandez-Gomez C, Correa A, Alvarez C, Rosso F, Matta L, Luna C, Zurita J, et al. Characterization and clinical impact of bloodstream infection caused by Carbapenemase-producing Enterobacteriaceae in seven Latin American countries. PLoS One. 2016;11(4):e0154092.","journal-title":"PLoS One"},{"issue":"11","key":"4409_CR7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1017\/ice.2017.197","volume":"38","author":"PP Kohler","year":"2017","unstructured":"Kohler PP, Volling C, Green K, Uleryk EM, Shah PS, McGeer A. Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2017;38(11):1319\u201328.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7","key":"4409_CR8","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.3201\/eid2007.121004","volume":"20","author":"ME Falagas","year":"2014","unstructured":"Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20(7):1170\u20135.","journal-title":"Emerg Infect Dis"},{"issue":"3","key":"4409_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S1473-3099(16)00057-8","volume":"16","author":"X Yao","year":"2016","unstructured":"Yao X, Doi Y, Zeng L, Lv L, Liu JH. Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet Infect Dis. 2016;16(3):288\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"4409_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1473-3099(15)00424-7","volume":"16","author":"YY Liu","year":"2016","unstructured":"Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4409_CR11","first-page":"711","volume":"64","author":"LJ Rojas","year":"2017","unstructured":"Rojas LJ, Salim M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Marshall S, Rudin SD, et al. Colistin resistance in Carbapenem-resistant Klebsiella pneumoniae: laboratory detection and impact on mortality. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017;64(6):711\u20138.","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"key":"4409_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fmicb.2019.00080","volume":"10","author":"CC Sheu","year":"2019","unstructured":"Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by Carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80.","journal-title":"Front Microbiol"},{"issue":"2","key":"4409_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/17425255.2019.1563071","volume":"15","author":"I Karaiskos","year":"2019","unstructured":"Karaiskos I, Galani I, Souli M, Giamarellou H. Novel beta-lactam-beta-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant gram-negative pathogens. Expert Opin Drug Metab Toxicol. 2019;15(2):133\u201349.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"4409_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675\u201392.","journal-title":"Drugs"},{"issue":"6","key":"4409_CR15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.ijantimicag.2017.01.018","volume":"49","author":"F Krapp","year":"2017","unstructured":"Krapp F, Grant JL, Sutton SH, Ozer EA, Barr VO. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime\/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents. 2017;49(6):770\u20133.","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"4409_CR16","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for Carbapenem-resistant Enterobacteriaceae infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(12):1615\u20138.","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"3","key":"4409_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","volume":"68","author":"M Tumbarello","year":"2019","unstructured":"Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, Menichetti F, Viscoli C, Campoli C, Venditti M, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019;68(3):355\u201364.","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"key":"4409_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","volume":"59","author":"JJ Caston","year":"2017","unstructured":"Caston JJ, Lacort-Peralta I, Martin-Davila P, Loeches B, Tabares S, Temkin L, Torre-Cisneros J, Pano-Pardo JR. Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2017;59:118\u201323.","journal-title":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases"},{"issue":"2","key":"4409_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D van Duin","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/avibactam and Ceftolozane\/Tazobactam: second-generation beta-lactam\/beta-lactamase inhibitor combinations. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(2):234\u201341.","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"11","key":"4409_CR20","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1093\/jac\/dky295","volume":"73","author":"A Sousa","year":"2018","unstructured":"Sousa A, Perez-Rodriguez MT, Soto A, Rodriguez L, Perez-Landeiro A, Martinez-Lamas L, Nodar A, Crespo M. Effectiveness of ceftazidime\/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(11):3170\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"4409_CR21","doi-asserted-by":"crossref","unstructured":"Alotaibi F. Carbapenem-resistant Enterobacteriaceae: an update narrative review from Saudi Arabia. Journal of infection and public health. 2019.","DOI":"10.1016\/j.jiph.2019.03.024"},{"issue":"7","key":"4409_CR22","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/jac\/dkv086","volume":"70","author":"M Tumbarello","year":"2015","unstructured":"Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133\u201343.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"4409_CR23","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","volume":"17","author":"B Gutierrez-Gutierrez","year":"2017","unstructured":"Gutierrez-Gutierrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Pano-Pardo JR, Venditti M, Tumbarello M, Daikos G, Canton R, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726\u201334.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"4409_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;66(2):163\u201371.","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"key":"4409_CR25","doi-asserted-by":"crossref","unstructured":"Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-Vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including Carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9).","DOI":"10.1128\/AAC.00567-17"},{"key":"4409_CR26","doi-asserted-by":"crossref","unstructured":"Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF. In vitro activity of the Siderophore cephalosporin, Cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including Carbapenem-nonsusceptible isolates (SIDERO-WT-2014 study). Antimicrob Agents Chemother. 2017;61(9).","DOI":"10.1128\/AAC.00093-17"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4409-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4409-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4409-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T23:05:49Z","timestamp":1599087949000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4409-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4409"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4409-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]},"assertion":[{"value":"27 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the institutional review board of King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia. No administrative permission were required to access data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AH works at Pfizer, anti infectives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"772"}}